120 related articles for article (PubMed ID: 28499650)
1. The Mesenchymal State Predicts Poor Disease-Free Survival in Resectable Non-Small Cell Lung Cancer.
Mehta K; Moravcikova E; McFall D; Luketich JD; Pennathur A; Donnenberg AD; Donnenberg VS
Ann Thorac Surg; 2017 Jul; 104(1):321-328. PubMed ID: 28499650
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of cancer stem cells, epithelial-mesenchymal transition and circulating tumor cells in lung cancer.
Pirozzi G; Tirino V; Camerlingo R; La Rocca A; Martucci N; Scognamiglio G; Franco R; Cantile M; Normanno N; Rocco G
Oncol Rep; 2013 May; 29(5):1763-8. PubMed ID: 23426441
[TBL] [Abstract][Full Text] [Related]
3. Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer.
Siegfried JM; Weissfeld LA; Singh-Kaw P; Weyant RJ; Testa JR; Landreneau RJ
Cancer Res; 1997 Feb; 57(3):433-9. PubMed ID: 9012470
[TBL] [Abstract][Full Text] [Related]
4. [Predicting efficacy of neoadjuvant cheomotherapy on resectable stage IIIA non-small cell lung cancer by multi-gene expressions].
Cheng C; Wu YL; Gu LJ; Chen G; Weng YM; Feng WN; Zhong WZ
Ai Zheng; 2005 Jul; 24(7):846-9. PubMed ID: 16004813
[TBL] [Abstract][Full Text] [Related]
5. CXCR4 is involved in CD133-induced EMT in non-small cell lung cancer.
Tu Z; Xie S; Xiong M; Liu Y; Yang X; Tembo KM; Huang J; Hu W; Huang X; Pan S; Liu P; Altaf E; Kang G; Xiong J; Zhang Q
Int J Oncol; 2017 Feb; 50(2):505-514. PubMed ID: 28000861
[TBL] [Abstract][Full Text] [Related]
6. Epithelial-mesenchymal transition in patients of pulmonary adenocarcinoma: correlation with cancer stem cell markers and prognosis.
Sung WJ; Park KS; Kwak SG; Hyun DS; Jang JS; Park KK
Int J Clin Exp Pathol; 2015; 8(8):8997-9009. PubMed ID: 26464642
[TBL] [Abstract][Full Text] [Related]
7. Putative stem cell markers in non-small-cell lung cancer: a clinicopathologic characterization.
Sterlacci W; Savic S; Fiegl M; Obermann E; Tzankov A
J Thorac Oncol; 2014 Jan; 9(1):41-9. PubMed ID: 24346092
[TBL] [Abstract][Full Text] [Related]
8. [Expression and significance of CD44(+)ESA(+)CD24(-/low), stem cell markers for breast cancer, in non-small-cell lung carcinoma].
Lu ZQ; Li HG; Zhang HZ; Fan MJ; Shen XM; He XX
Ai Zheng; 2008 Jun; 27(6):575-9. PubMed ID: 18570728
[TBL] [Abstract][Full Text] [Related]
9. High expression of the transcriptional co-activator p300 predicts poor survival in resectable non-small cell lung cancers.
Hou X; Li Y; Luo RZ; Fu JH; He JH; Zhang LJ; Yang HX
Eur J Surg Oncol; 2012 Jun; 38(6):523-30. PubMed ID: 22440742
[TBL] [Abstract][Full Text] [Related]
10. Aberrant expression of cancer stem cell markers (CD44, CD90, and CD133) contributes to disease progression and reduced survival in hepatoblastoma patients: 4-year survival data.
Bahnassy AA; Fawzy M; El-Wakil M; Zekri AR; Abdel-Sayed A; Sheta M
Transl Res; 2015 Mar; 165(3):396-406. PubMed ID: 25168019
[TBL] [Abstract][Full Text] [Related]
11. Do tumours located in the left lower lobe have worse outcomes in lymph node-positive non-small cell lung cancer than tumours in other lobes?
Kudo Y; Saji H; Shimada Y; Nomura M; Usuda J; Kajiwara N; Ohira T; Ikeda N
Eur J Cardiothorac Surg; 2012 Sep; 42(3):414-9. PubMed ID: 22398463
[TBL] [Abstract][Full Text] [Related]
12. Increased levels of tumor-infiltrating lymphocytes are associated with improved recurrence-free survival in stage 1A non-small-cell lung cancer.
Horne ZD; Jack R; Gray ZT; Siegfried JM; Wilson DO; Yousem SA; Nason KS; Landreneau RJ; Luketich JD; Schuchert MJ
J Surg Res; 2011 Nov; 171(1):1-5. PubMed ID: 21571304
[TBL] [Abstract][Full Text] [Related]
13. Prognostic markers in resectable non-small cell lung cancer: a multivariate analysis.
Pelletier MP; Edwardes MD; Michel RP; Halwani F; Morin JE
Can J Surg; 2001 Jun; 44(3):180-8. PubMed ID: 11407827
[TBL] [Abstract][Full Text] [Related]
14. Survival following resection of clinically occult N2 non small cell lung cancer.
Dalton R; Keller S
J Cardiovasc Surg (Torino); 1994 Dec; 35(6 Suppl 1):13-7. PubMed ID: 7775526
[TBL] [Abstract][Full Text] [Related]
15. Dickkopf-1-promoted vasculogenic mimicry in non-small cell lung cancer is associated with EMT and development of a cancer stem-like cell phenotype.
Yao L; Zhang D; Zhao X; Sun B; Liu Y; Gu Q; Zhang Y; Zhao X; Che N; Zheng Y; Liu F; Wang Y; Meng J
J Cell Mol Med; 2016 Sep; 20(9):1673-85. PubMed ID: 27240974
[TBL] [Abstract][Full Text] [Related]
16. Pathologic lymph node staging practice and stage-predicted survival after resection of lung cancer.
Osarogiagbon RU; Allen JW; Farooq A; Berry A; O'Brien T
Ann Thorac Surg; 2011 May; 91(5):1486-92. PubMed ID: 21524460
[TBL] [Abstract][Full Text] [Related]
17. False-positivity of mediastinal lymph nodes has negative effect on survival in potentially resectable non-small cell lung cancer.
Iskender I; Kadioglu SZ; Cosgun T; Kapicibasi HO; Sagiroglu G; Kosar A; Kir A
Eur J Cardiothorac Surg; 2012 Apr; 41(4):874-9. PubMed ID: 22423060
[TBL] [Abstract][Full Text] [Related]
18. A three gene-based risk score predicts prognosis of resected non-small-cell lung cancer.
Liu K; Chen HL; Gu MM; You QS
Int J Clin Exp Pathol; 2015; 8(12):16081-8. PubMed ID: 26884885
[TBL] [Abstract][Full Text] [Related]
19. The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer.
Le H; Zeng F; Xu L; Liu X; Huang Y
Mol Med Rep; 2013 Nov; 8(5):1511-8. PubMed ID: 24008862
[TBL] [Abstract][Full Text] [Related]
20. Decreased pretreatment serum cholesterol level is related with poor prognosis in resectable non-small cell lung cancer.
Li JR; Zhang Y; Zheng JL
Int J Clin Exp Pathol; 2015; 8(9):11877-83. PubMed ID: 26617943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
